Novartis says Swissmedic approves heart medicine Entresto
Friday, September 18, 2015
Novartis AG says Swissmedic approves Novartis' new heart failure medicine Entresto.
Decision by Swiss Health Authority follows U.S. Food and Drug Administration (FDA) approval of Entresto in July.
Entresto is indicated in Switzerland to reduce the risk of cardiovascular mortality and morbidity in patients with heart failure with reduced ejection fraction.
reuters.com
